Rybrevant plus Lazcluze significantly extends overall survival in EGFR-mutated NSCLC compared to Tagrisso, with benefits continuing beyond the follow-up period. The combination therapy improves ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced new paradigm changing findings from the ...

ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best healthcare penny stocks to buy now. On September 8, 2025, ImmunityBio Inc. unveiled promising Phase 2 QUILT-3.055 trial results at the IASLC World ...

Recent treatment innovations for lung cancer and melanoma have improved survival overall but also increased disparities in survival according to income, researchers found.

A combination of Iza-bren and Tagrisso showed beneficial results as an initial treatment for advanced/metastatic EGFR-mutated ...

Positive results from the final overall survival (OS) analysis of the FLAURA2 Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) with the addition of pemetrexed and platinum-based chemothera ...

Please provide your email address to receive an email when new articles are posted on . CAN-2409 plus valacyclovir nearly doubled survival compared with docetaxel for patients who had inadequate ...

Final overall survival (OS) results from the Phase III FLAURA2 trial demonstrate that first-line osimertinib plus ...

The ORR is down slightly from the rate seen in an earlier stage of the trial, in which the B7-H3-directed ADC was tied to a ...

Results from the Phase III FLAUR2 trial (NCT04035486) showed that Tagrisso combined with pemetrexed and platinum-based ...

Yes, lung cancer can be curable — if it’s found early and responds well to treatment. Thanks to recent therapy advances, the lung cancer mortality rate has declined and survival rates have improved.

Racial and ethnic disparities persist in the treatment of metastatic cancer among Medicare fee-for-service beneficiaries, ...